{"id":561556,"date":"2021-09-06T13:38:01","date_gmt":"2021-09-06T13:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=561556"},"modified":"2021-09-06T13:38:01","modified_gmt":"2021-09-06T13:38:01","slug":"gauchers-disease-pipeline-analysis-shows-tremendous-growth-opportunities-for-the-upcoming-years-in-the-domain","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/gauchers-disease-pipeline-analysis-shows-tremendous-growth-opportunities-for-the-upcoming-years-in-the-domain_561556.html","title":{"rendered":"Gaucher\u2019s Disease pipeline analysis shows tremendous growth opportunities for the upcoming years in the domain"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1630901771.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Gaucher&rsquo;s Disease pipeline analysis shows tremendous growth opportunities for the upcoming years in the domain\" src=\"https:\/\/www.abnewswire.com\/uploads\/1630901771.png\" alt=\"Gaucher&rsquo;s Disease pipeline analysis shows tremendous growth opportunities for the upcoming years in the domain\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Gaucher&#8217;s Disease Pipeline <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s Gaucher&#8217;s Disease pipeline report provides comprehensive insights into the current clinical development scenario and growth prospects in the Gaucher&#8217;s disease market. A detailed picture of Gaucher&#8217;s disease pipeline landscape is provided, including a disease overview and treatment guidelines for Gaucher&#8217;s disease.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/57a36db31bd7c86bc230496c4b44c3fe.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&#8217;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/gauchers-disease-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Gaucher&#8217;s Disease pipeline report<\/a><\/strong> provides comprehensive insights into the current clinical development scenario and growth prospects in the Gaucher&#8217;s disease market. A detailed picture of Gaucher&#8217;s disease pipeline landscape is provided, including a disease overview and treatment guidelines for Gaucher&#8217;s disease.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the Key Highlights from the Gaucher&rsquo;s Disease Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Gaucher&rsquo;s Disease pipeline comprises therapies that are in different stages of the clinical phase include <strong>Venglustat, Arimoclomol, PR-001, AVR-RD-02, M 011, GBA programme<\/strong>, and others that are expected to be available for Gaucher&rsquo;s Disease treatment soon.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Several pharmaceutical companies are evaluating their drug candidates for Gaucher&#8217;s Disease treatment include <strong>Sanofi, Orphazyme, Prevail Therapeutics, AvroBio, M6P Therapeutics, Gain therapeutics,<\/strong> among others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The therapies that are in late phase (Phase II\/III) of development for Gaucher&rsquo;s Disease include <strong>Venglustat (Sanofi),<\/strong> and others whereas <strong>Arimoclomol (Orphazyme)<\/strong> is in Phase II of Gaucher&rsquo;s Disease clinical trials.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Some therapies such as <strong>M 011, GBA programme<\/strong>, along with others are still in the early phase of development i.e. preclinical stage for Gaucher&rsquo;s Disease treatment.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">For more information, request sample @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/gauchers-disease-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Gaucher&rsquo;s Disease Pipeline Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Gaucher&rsquo;s Disease: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Gaucher Disease is a rare, inherited metabolic disorder characterized by a lack of the enzyme glucocerebrosidase, which causes an accumulation of harmful amounts of certain fats (lipids), specifically the glycolipid glucocerebroside, throughout the body, particularly in the bone marrow, spleen, and liver. Gaucher disease symptoms and physical findings vary greatly from patient to patient. There are three types of Gaucher&rsquo;s Disease- Gaucher Disease Type 1, Gaucher Disease Type 2, and Gaucher Disease Type 3.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Gaucher&rsquo;s Disease Symptoms<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Gaucher&rsquo;s Disease symptoms differ from person to person. Many people&#8217;s symptoms start in childhood. Some people experience only minor symptoms. Gaucher&rsquo;s Disease symptoms can include:&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Enlarged Spleen<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Enlarged Liver<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Eye Movement Disorders<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Yellow Spots in the Eyes<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Seizures<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bone Pain and Fracture<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Gaucher&rsquo;s Disease Treatment<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Gaucher Disease Type 1 is treatable with regular therapy. Gaucher Disease treatments either increase enzyme levels or decrease the fatty substance that accumulates in the body as a result of Gaucher Disease. The neurological damage caused by Gaucher Disease Types 2 and 3 has no treatment. Gaucher&rsquo;s Disease treatments available include enzyme replacement therapy (ERT) and substrate reduction therapy (SRT).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Gaucher&rsquo;s Disease Pipeline Analysis: Drug Profiles<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Venglustat: Sanofi<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Product Description<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Venglustat developed by Sanofi is a small-molecule glucosylceramide synthase (GCS) inhibitor that is designed to reduce the production of glucosylceramide (GL-1) and thus the formation of glucosylceramide-based glycosphingolipids.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Phase II\/III<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>NCT02843035:<\/strong> Sanofi launched a three-part study in January 2017 to assess the efficacy and safety of Venglustat in combination with Cerezyme in adult and pediatric patients with Gaucher disease type 3 (GD3) receiving open-label long-term treatment.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Gaucher&rsquo;s Disease Pipeline Therapies and Key Companies<\/strong>&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Venglustat: Sanofi&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Arimoclomol: Orphazyme<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">PR-001: Prevail Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AVR-RD-02: AvroBio<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">M 011: M6P Therapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">GBA programme: Gain therapeutics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get more details on the emerging therapies @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/gauchers-disease-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Gaucher&rsquo;s Disease Treatment Gene Therapy<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Gaucher&rsquo;s Disease Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">By Product Type<\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Monotherapy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Combination Therapy<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">By Stage<\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discovery<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-Clinical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phase I<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phase II<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phase III<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-registration<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">By Route of Administration<\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Inhalation<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravenous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subcutaneous<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">By Molecule Type<\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small Molecule<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Stem Cell Therapy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gene Therapy<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Targets<\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Immune System<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Multiple Kinase<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">By Mechanism of Action<\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Protease Inhibitors<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Immunomodulatory<\/p>\n<\/li>\n<\/ul>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the Report<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Coverage:<\/strong> Global<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Gaucher&rsquo;s Disease Key Players:<\/strong> Sanofi, Orphazyme, Prevail Therapeutics, AvroBio, M6P Therapeutics, Gain therapeutics, among others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Gaucher&rsquo;s Disease Pipeline Therapies:<\/strong> Venglustat, Arimoclomol, PR-001, AVR-RD-02, M 011, GBA programme, and others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"87\" \/>\n<col width=\"537\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\">1.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">2.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">3.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Gaucher&#8217;s Disease: Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">4.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Gaucher&#8217;s Disease Pipeline Therapeutics<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">5.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Gaucher&#8217;s Disease Late Stage Products (Phase III)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">6.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Gaucher&#8217;s Disease Mid Stage Products (Phase&nbsp; II\/III)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">7.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Gaucher&#8217;s Disease Mid Stage Products (Phase II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">8.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Gaucher&#8217;s Disease Early Stage Products (Phase&nbsp; I\/II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">9.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Gaucher&#8217;s Disease Early stage products (Phase I\/II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">10.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Gaucher&#8217;s Disease Preclinical and Discover Stage Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">11.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Gaucher&#8217;s Disease Preclinical and Discover Stage Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">12.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Gaucher&#8217;s Disease Therapeutic Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">13.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Gaucher&#8217;s Disease Inactive Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">14.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Gaucher&#8217;s Disease Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">15.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Gaucher&#8217;s Disease Key Companies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">16.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Gaucher&#8217;s Disease Key Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">17.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Gaucher&#8217;s Disease- Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">18.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Gaucher&#8217;s Disease- Market Drivers and Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">19.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Gaucher&#8217;s Disease- Future Perspectives and Conclusion<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">20.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Gaucher&#8217;s Disease Analyst Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">21.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">22.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">For rich insights into Healthcare and Pharmaceutical News, visit <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Pharma, Healthcare, and Biotech Blog Posts<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key questions answered in the Gaucher&rsquo;s Disease Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">What are the treatment options for Gaucher&#8217;s Disease?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">How many pharmaceutical companies are working on Gaucher&#8217;s Disease treatments?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Which of these companies&#8217; pharmaceuticals is the most commonly used?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">What is the total number of Gaucher&#8217;s Disease medications produced by each company?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">How many drugs in the early, mid, or late stages of development for Gaucher&#8217;s Disease are there?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">How many of the current therapies in development can be used alone or in combination with other treatments?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">What are the most significant industry-industry and industry-academy collaborations, mergers and acquisitions, and licensing practices that have an impact on Gaucher&#8217;s Disease?<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/gaucher-disease-type-1-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Gaucher Disease Type 1 Pipeline Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get a comprehensive analysis of Gaucher Disease Type 1 pipeline therapies and key companies including <strong>Sanofi, Orphazyme, Prevail Therapeutics,<\/strong> among others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=gauchers-disease-pipeline-analysis-shows-tremendous-growth-opportunities-for-the-upcoming-years-in-the-domain\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=gauchers-disease-pipeline-analysis-shows-tremendous-growth-opportunities-for-the-upcoming-years-in-the-domain\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gaucher&#8217;s Disease Pipeline DelveInsight&#8217;s Gaucher&#8217;s Disease pipeline report provides comprehensive insights into the current clinical development scenario and growth prospects in the Gaucher&#8217;s disease market. A detailed picture of Gaucher&#8217;s disease pipeline landscape is provided, including a disease overview and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/gauchers-disease-pipeline-analysis-shows-tremendous-growth-opportunities-for-the-upcoming-years-in-the-domain_561556.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-561556","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/561556","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=561556"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/561556\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=561556"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=561556"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=561556"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}